PRF Technologies Ltd.
PRF Technologies Ltd. (PRFX): 4 pipeline candidates · 7 upcoming catalysts · ~3 mo cash runway · 12 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
2.7 months
D/E 0.32 · 0% dilution
Lead: Approved
4 candidates
7 upcoming, next in ~1377d
N/A
A transparent, data-derived signal for PRF Technologies Ltd.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7M
Cash
$3.1M
Quarterly Burn
$4.0M
Runway
2.7 mo
Revenue
$17K
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| aroxxen | Phase 2 |
| aur107 | Phase 1 |
| buprenorphine | Approved |
| leniolisib | Phase 2 |
Upcoming Catalysts (7)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$30K
| Holder | Shares | Value |
|---|---|---|
| citadel advisors llc | 13,220 | $27K |
| morgan stanley | 1,611 | $3K |
| osaic holdings, inc. | 40 | $80 |
Frequently asked questions
How many drug candidates are in PRF Technologies Ltd.'s pipeline?
PRF Technologies Ltd. (PRFX) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PRF Technologies Ltd.'s lead drug candidate?
PRF Technologies Ltd.'s most advanced tracked candidate is aroxxen (Phase 2) for Coronary Artery Disease.
What is PRF Technologies Ltd.'s next catalyst?
PRF Technologies Ltd.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: SUBOXONE" — expected March 26, 2030.
What is PRF Technologies Ltd.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PRF Technologies Ltd. has approximately 2.7 months of cash runway.
What is PRF Technologies Ltd.'s market capitalization?
PRF Technologies Ltd.'s market capitalization is approximately $1.7M.
Get the full picture on PRF Technologies Ltd.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.